SLC5A2 and cirrhosis of liver: Since these pathways are also involved in the pathophysiology of liver cirrhosis (Zhou et al., 2014[108]; Lee et al., 2022[48]; Nan et al., 2022[61]), their modulation using SGLT2 inhibitors in diabetic patients may be a new promising strategy to reduce the risk of liver cirrhosis.